Search
Immunology_Flyer_BIO-2021.pdf
Partnering_In_IMMUNOLOGY_0.pdf
Partnering in Immunology & Resp MAY 2024 CORP.pdf
Partnering in Immunology & Inflammation MAY 2024 CORP_0.pdf
Immunology_Partnering_Interests_2018-12.pdf
Horses
Horses
Live well with Generalized Pustular Psoriasis (GPP)
Unmet needs in Generalized Pustular Psoriasis (GPP)
Generalised-Pustular-Psoriasis-Infographic
What is GPP? GPP is a rare and chronic autoinflammatory skin disease with recurrent episodes of exacerbations or flares
Our Partners_ViraTherapeutics
Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
SIRPα antagonist
SIRPα antagonist
GPP
GPP
BI 764532
DLL3/CD3 T-cell engager
BI 764532
DLL3/CD3 T-cell engager
BI 764532
DLL3/CD3 T-cell engager: DLL3/CD3 T-cell engager
DLL3/CD3 T-cell engager
DLL3/CD3 T-cell engager
New cancer therapeutics collaboration with 3T Bio
Boehringer Ingelheim and 3T Biosciences collaborate to discover and develop next-generation cancer therapies to address high unmet patient needs
CD137/FAP agonist
CD137/FAP agonist
B7-H6/CD3 T-Cell Engager
B7-H6/CD3 T-Cell Engager
KISIMA® cancer vaccine
KISIMA® Cancer Vaccine
Targeting Tumor Stroma
Boehringer Ingelheim’s research approach in stromal biology may lead to new medicines that will change the face of cancer and give new hope to patients
VSV-GP
VSV-GP
Advancing health: Our impactful R&D investments
Discover how we’re investing in sustainable impact with an unwavering commitment to research and development
Technologies
We are expanding our global network of technology partners Learn more about partnering with us.